Sandur Manganese Q2 FY27: Consolidated PAT Up 87% YoY to ₹260 Cr as Margins Expand
PAT +87.43% YoY · revenue +22.22% · margins expanding
₹1,506.13 Cr
+22.22% YoY
₹260.28 Cr
+87.43% YoY
17.13%
+6pp YoY
₹5.35
The Sandur Manganese & Iron Ores (SMIORE) board approved unaudited results for Q2 FY27 (quarter ended 30 September 2026) on 3 November 2026. On a consolidated basis — the primary read, since the group spans mining, ferroalloys, coke & energy and a materially larger Steel segment held through subsidiaries — revenue came in at ₹1,506.13 Cr, up 22.2% YoY from ₹1,232.34 Cr and 9.6% QoQ from ₹1,374.78 Cr. Net profit attributable to owners was ₹260.28 Cr, up 87.4% YoY (₹138.87 Cr) and 14.2% QoQ (₹227.85 Cr); adjusted for a ₹9.3 Cr one-off exceptional gain this quarter, underlying YoY PAT growth is closer to ~82%, still a strong beat on both counts. Standalone PAT was ₹177.52 Cr on revenue of ₹582.28 Cr, reflecting only the core mining/ferroalloy/coke business without the Steel segment.
Q2 FY-2027 vs prior quarters
The quarter's exceptional item is a ₹9.32 Cr credit from reversing an earlier gratuity-liability provision after the Group revised its wage structure following the new Labour Codes effective 1 April 2026 — a genuine one-off, not an operating gain. Margins expanded on both counts: consolidated NPM rose to 17.3% from 11.2% a year ago and 16.4% last quarter; operating margin (PBIDT/revenue) improved to ~25.9% from 22.1% YoY. By segment, the gain is overwhelmingly a Steel story — segment result more than doubled YoY to ₹103.74 Cr from ₹40.22 Cr (+157.9%) and was up 22.3% QoQ, while Steel segment revenue grew a more modest 16.2% YoY, pointing to spread/realisation gains rather than volume. Mining, the core legacy business, also grew profit 25.9% YoY to ₹246.68 Cr on stronger ore revenue (₹476.2 Cr, +36.4% YoY). Ferroalloys and coke & energy were smaller, broadly flat-to-modestly-higher contributors.
The stock went into the print at ₹164.2, down 7.6% over the past month of trading.
For context: this is the second-highest quarterly PAT of the last 6 quarters.
No street consensus estimates for this specific quarter could be located — SMIORE does not appear to carry formal sell-side coverage with published Q2 FY27 previews, so vsStreet is unknown rather than a miss or beat. Management has not issued formal numeric guidance for FY27 in our records or in public filings found, so this print cannot be graded against a stated target. The result arrives alongside two board actions: approval of an investment of up to ₹200 Cr in Royal Sandur MedTech Private Limited (the newly incorporated wholly owned medical-devices subsidiary, part of the company's October 2026 foray into medical devices), and the resignation of independent director Dr. Latha Pillai effective 4 November 2026 alongside the appointment of G. P. Kundargi (former MOIL CMD) as a non-executive additional director from 12 November 2026, subject to shareholder approval. Neither governance change affects the operating numbers. No separate management press release or earnings commentary accompanied this filing — only the SEBI outcome-of-board-meeting letter and reviewed financial statements — so there is no management framing to reconcile against the print.
W1
Steel segment spread/margin sustainability after segment result jumped to ₹103.74 Cr (+157.9% YoY) — watch whether Q3 FY27 holds this level or reverts
W2
Drawdown pace and execution of the up to ₹200 Cr investment approved in Royal Sandur MedTech as the medical-devices foray scales
W3
Resolution of the compensatory afforestation dispute with Karnataka's DCF (SLP before the Supreme Court) — unresolved exposure on a ₹13,905 lakh demand tied to forest-lease renewal